
Contact details
Dr James M Flanagan
Research Fellow
Department of Surgery & Cancer
4th Floor
Institute of Reproductive and Developmental Biology
Hammersmith Campus
Tel: +44 (0)20 7594 1804
Email:
Dr James M Flanagan
Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics.
Current work is aimed at investigating germline epigenetic alterations as a mechanism for carcinogenesis funded by Breast Cancer Campaign and Cancer Research UK.
Current projects include DNA methylation profiling to define tumour subgroups, identification of epigenetic risk markers in breast cancer patients, determining the prognostic value of epigenetic variability in somatic cells from patients in clinical trials and a recently funded project to investigate the use of DNA methylation for characterising pathogenicity of BRCA1 unknown variants.
Recent Publication in Cancer Research attracts Media Attention!
Media Attention attracts Blogs and Observations
We participate in the London Epigenomics Club
THANKS TO EVERYONE WHO HELPED US RAISE MONEY FOR BREAST CANCER CAMPAIGN WEAR IT PINK DAY
Recent Publications:
- Shenker NS, Polidoro S, van Veldhoven K, Sacerdote C, Ricceri F, Birrell MA, Belvisi MG, Brown R, Vineis P, Flanagan JM. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet. 2012 Nov 21. [Epub ahead of print]. PMID:23175441
- Brennan, K. and FLANAGAN J.M. Is there a genuine link between genome-wide hypomethylation cancer risk? (in press, Cancer Prevention Research)
- Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, Swerdlow A, KConFab Investigators, Riboli E, Vineis P, Dorronsoro M, Clavel-Chapelon F, Panico S, Onland-Moret NC, Trichopoulos D, Kaaks R, Khaw KT, Brown R, and FLANAGAN J.M. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. (Cancer Research. 2012 May 1;72(9):2304-2313.)
- Shenker, N and FLANAGAN J.M. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research (Br J Cancer, 2012 Jan 17;106(2):248-53)
- FLANAGAN J.M., et al .DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status (Am J Hum Genet. 2010 Mar 12;86(3):420-33.)


